Krogulski Kenneth has demonstrated a consistent buying pattern in CPIX (Cumberland Pharmaceuticals) shares, with no recorded sales across 150 transactions totaling $50,970 in acquired value, according to SEC filings. The most recent activity includes two notable purchases on March 18, 2026, valued at $11,200 and $5,040, both coded as open-market acquisitions (A). Prior to these, Krogulski engaged in a steady accumulation of CPIX shares through smaller, near-daily purchases coded as derivative transactions (L) between late November and December 2025. These transactions ranged from $212.76 on December 30, 2025, to $340.08 on December 16, 2025, with no clear directional trend in purchase size.
The absence of any sell transactions suggests a long-term accumulation strategy focused exclusively on CPIX. The frequency of purchases—particularly the cluster of 24 acquisitions in December 2025—indicates sustained interest rather than sporadic trading. While the derivative transaction codes (L) suggest these may involve options or other instruments, the open-market buys in March 2026 reflect direct equity exposure. The data reveals no diversification across other tickers, with CPIX remaining the sole holding in Krogulski’s reported activity. The pattern aligns with a buyer who has consistently added to their position without taking profits, though the rationale remains undisclosed in regulatory filings.
AI-assisted summary